Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Pharmacokinetics (including PopPK, ADME, Biopharmaceutics)
Pharmacokinetics (including PopPK, ADME, Biopharmaceutics)
Type here to filter the list
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Favorite
A004: Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Favorite
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Favorite
A005: Implications of Being Born Small for Gestational Age on the Exposure of Vancomycin & Gentamicin In Neonates
Favorite
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Favorite
A006: Microfluidic Blood-Milk Barrier & Physiologically-based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk
Favorite
060: Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Favorite
061: First-in-Human Evaluation of Pharmacokinetics & Safety of Tilpisertib Fosmecarbil, an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor, in Healthy Volunteers
Favorite
062: Absolute Oral Bioavailability of Nerandomilast in Healthy Male Study Participants
Favorite
063: Preclinical & Clinical Pharmacokinetics of JNJ-75220795, A siRNA Therapeutic Targeting
PNPLA3
, for Metabolic-associated Steatohepatitis
Favorite
064: Pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian Healthy Adults & Adults With Uncomplicated Malaria
Favorite
065: Clinical Pharmacological Characterization of Cilta-cel, a CAR-T Therapy Directed Against BCMA in Adult Patients With Multiple Myeloma in a Multicohort CARTITUDE-2 Study
Favorite
066: Population Pharmacokinetic Analysis of Cenobamate
Favorite
067: The Impact of Late-Runner Participants on PK Variability in Healthy Volunteer, Single-Ascending Dose Trials
Favorite
068: Pharmacokinetic Analyses & Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia
Favorite
069: Population Pharmacokinetics of Bictegravir in Pregnant & Postpartum Persons Living With HIV
Favorite
070: Population Pharmacokinetic & Exposure-Response Analyses for the Phase 3 PhALLCON Study of Ponatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Favorite
071: Evaluation of Palbociclib & Combinatorial Chemotherapy Pharmacokinetics in Pediatric Patients With Recurrent or Refractory Solid Tumors
Favorite
072: Pharmacokinetics & Pharmacodynamics of Milvexian After Administration Every 12 Hours in Healthy Subjects
Favorite
073: Clinical Pharmacology of Bemarituzumab in Gastric & Gastroesophageal Junction Cancer Patients Supports the Interchangeability of Q2W & Q3W Dosing Regimens
Favorite
074: A First-in-Human, Single & Multiple Ascending Dose Study of CK-4021586, A Novel Cardiac Myosin Inhibitor
Favorite
075: Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Favorite
076: First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers
Favorite
153: Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02385 in Patients With Select Advanced Malignancies
Favorite
154: Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
Favorite
155: The Human Metabolism of Lufotrelvir, a Prodrug for the Treatment of SARS-COV2, Investigated By LC+AMS
Favorite
156: Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
Favorite
157: Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
Favorite
158: Model-Informed Development of Recombinant
Erwinia
Asparaginase (JZP458) in Patients With Acute Lymphoblastic Leukemia
Favorite
159: Pharmacokinetics, Pharmacodynamics & Safety of Budigalimab, An Anti-PD-1 Monoclonal Antibody, in People Living With HIV-1
Favorite
160: Modeling Age-related Changes in Kidney Function Using Aminoglycoside Clearance as a Surrogate: Can Body Composition Help?
Favorite
161: Comparison of Nicotine Pharmacokinetic & Subjective Profiles of Three Modern Oral Nicotine Products & a Snus Product
Favorite
162: Pharmacokinetics of DYP688 in Patients With Metastatic Uveal Melanoma & Other GNAQ/11 Mutant Melanomas
Favorite
163: GLP-1-Induced Delays in GI Motility & Their Effects on Co-Administered Drug Absorption: A PBPK Analysis
Favorite
